menu
    • menu

    Company profile for Enterprise Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. The company is backed by top tier venture capital investors and is based in the UK with offices at the University of Sussex Innovation Centre. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. Ente...
    Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. The company is backed by top tier venture capital investors and is based in the UK with offices at the University of Sussex Innovation Centre. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. Enterprise Therapeutics’ scientific strategy is aimed at discovering new disease modifying therapies that target the underlying mechanisms of mucus congestion, which will reduce the frequency of lung infections.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Enterprise Therapeuticsunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Sussex Innovation Centre University of Sussex Science Park Square Falmer Brigh...
    Telephone
    Telephone
    +44 (0)1273 234667
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://enterprisetherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/enterprise-therapeutics
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/enterprisethera?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Enterprise Therapeutics Publishes on ETD001 for Cystic Fibrosis
    Enterprise Therapeutics Publishes on ETD001 for Cystic Fibrosis

    19 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241119742592/en

    BUSINESSWIRE
    19 Nov 2024
    Share Share
    Enterprise Therapeutics Gets Rare Pediatric Designation
    Enterprise Therapeutics Gets Rare Pediatric Designation

    26 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240926150212/en

    BUSINESSWIRE
    26 Sep 2024
    Share Share
    Enterprise Therapeutics Doses First CF Patient In ETD001 Phase 2 Trial
    Enterprise Therapeutics Doses First CF Patient In ETD001 Phase 2 Trial

    23 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240723858841/en

    BUSINESSWIRE
    23 Jul 2024
    Share Share
    Enterprise Therapeutics Publishes Preclinical Profile Of ETD001
    Enterprise Therapeutics Publishes Preclinical Profile Of ETD001

    12 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240612597796/en

    BUSINESSWIRE
    12 Jun 2024
    Share Share
    Enterprise Therapeutics Closes £26 million Series B Follow-on Financing
    Enterprise Therapeutics Closes £26 million Series B Follow-on Financing

    30 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240130603297/en

    BUSINESSWIRE
    30 Jan 2024
    Share Share
    Enterprise Therapeutics doses first subjects in Phase I trial with ETD001
    Enterprise Therapeutics doses first subjects in Phase I trial with ETD001

    14 Jun 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210614005282/en

    BUSINESSWIRE
    14 Jun 2021
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search